The effect of restoring sinus rhythm by pulmonary vein isolation (PVI) on the quality of life (QOL) of patients with persistent atrial fibrillation (PerAF) has not been adequately investigated. This study was performed to compare the changes in QOL after extended PVI between patients with PerAF and paroxysmal AF (PAF).
R ecent clinical trials have shown that radiofrequency catheter ablation significantly improves the quality of life (QOL) of patients with symptomatic paroxysmal atrial fibrillation (PAF). [1] [2] [3] [4] Several questionnaires and scoring systems are available to evaluate the QOL in patients with AF, such as the Short Form-36 (SF-36), SF-12, EuroQOL, AF-QOL, European Heart Rhythm Association (EHRA) AF symptom scale, and AF Quality of Life Questionnaire. 5) The SF-36 is the most widely validated of these scoring systems, and extensive studies have used the SF-36 to assess the QOL in patients with PAF. Both the physical component summary (PCS) and mental component summary (MCS) scores assessed by the SF-36 improved after pulmonary vein isolation (PVI) in patients with PAF. However, the effect of restoring sinus rhythm by PVI on improvement in the QOL in patients with persistent AF (PerAF) has not been adequately investigated. This study was performed to compare the effects of restoring sinus rhythm by extended PVI on QOL between patients with PerAF and those with PAF and to study the predictive factors of improvement in QOL by PVI.
Methods

Study population and design:
Consecutive patients with PAF (n = 38) and PerAF (n = 22) who developed no AF recurrence 6 months after their first PVI from April 2014 to April 2016 were enrolled. A patient was excluded if any of the following were present: a low left ventricular ejection fraction (LVEF) of < 45% before the procedure, a history of PVI, they could not come to our outpatient clinic 6 months after the procedure, written informed consent was not obtained, and recurrence of AF after the 12week blanking period. Although there is currently no agreement on the duration of the blanking period, 6) we defined the blanking period according to the current guidelines. 7) PAF was defined as the occurrence of two or more episodes of AF during the previous year, all of which terminated spontaneously within 1 week. PerAF was defined KATO, ET AL as continuous AF that was sustained for > 7 days. Patients with longstanding PerAF with a duration of > 24 months were also excluded. The study protocol was approved by the institutional review board, and written informed consent was obtained from each patient before the procedure.
The detailed PVI procedure is described in our previous article. 8) QOL and other measurements: The QOL was surveyed at baseline and 6 months post-ablation using the Medical Outcome Study SF-36 survey. This survey assesses 8 aspects of the health status of a patient: physical functioning (PF), role limitations due to physical health (RP), mental health (MH), role limitations due to emotional problems (RE), social functioning (SF), bodily pain (BP), general health (GH), and vitality (VT). The PCS comprises the PF, RP, BP, and GH, and the MCS is computed using 4 other aspects: the VT, SF, RE, and MH. All responses are scored on a scale from 0 to 100, with 100 representing the best possible functioning status. Plasma B-type natriuretic peptide (BNP) measurements and conventional echocardiography were also conducted before and 6 months after PVI. The left atrial diameter (LAD) and LVEF were evaluated as previously described. 9,10) Follow-up: Patients with recurrence were discharged on their antiarrhythmic drugs, which were continued until the end of the blanking period and then discontinued. Patients with AF recurrence after the blanking period were given antiarrhythmic drugs, offered a repeat ablation, and excluded from the study.
All patients were followed up for 6 months after the ablation. At 3 and 6 months after the procedure, a cardiology evaluation involving 12-lead electrocardiography and 24-hour or 7-day Holter monitoring was conducted. Statistical analyses: Continuous data are presented as the mean ± standard deviation, and categorical data are presented as the count and percentage. Differences between two groups were assessed using the independentsamples t-test and Fisher's exact test for continuous and categorical variables, respectively. Paired t-tests were used to compare the data between baseline and follow-up. The change in each parameter (Δ) was calculated as the value at 6 months after PVI minus the baseline value. A multi-ple regression analysis was used to assess the factors that determined the ΔMCS or ΔPCS. Parameters associated with the ΔMCS or ΔPCS were entered into the multivariate model. The statistical analyses were performed using R software version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria), and a P value of < 0.05 was considered statistically significant.
Results
Patient characteristics:
At baseline, the sex, age, LAD, and LVEF were not different between the PerAF and PAF groups. Asymptomatic patients were mainly included in the PerAF group (EHRA symptom classification I: 90.9% in PerAF versus 5.6% in PAF, P < 0.001). The BNP level was higher in the PerAF group than in the PAF group (154.7 ± 93.5 versus 104.5 ± 70.3 pg/mL, P = 0.022). The demographic and clinical characteristics of the study population are summarized in Tables I and II . Complications of AF ablation: No patients developed PVI-associated vascular access accidents, cardiac perforation/tamponade, thromboembolic events, PV stenosis, extracardiac injury (e.g., esophageal injury), or nerve damage. To confirm the absence of PV stenosis in the chronic phase, all patients underwent multidetector-row computed tomography 6 months after PVI.
Effects of PVI on plasma BNP level, echocardiographic parameters, and heart rate:
The LAD and BNP level significantly decreased after PVI in both groups. Heart rate did not change after PVI in the PerAF group, but it increased in the PAF group (Table II) . The ΔBNP and ΔLAD were significantly greater in the PerAF group than in the PAF group (Table III) . QOL score: The QOL data at baseline and at the 6month follow-up were available in all patients (Table II) 10.0, P = 0.13). The ΔMCS was larger in the PAF group than in the PerAF group (Table III) . In contrast, the ΔPCS was larger in the PerAF than in the PAF group. A multivariate regression analysis of the ΔMCS was carried out for parameters with a P value of < 0.10 in the univariate analysis; these parameters included the baseline EF, base-line MCS, type of AF (PAF = 1), and ΔLAD. The results demonstrated that the baseline MCS and type of AF (PAF = 1) were independent predictors of the ΔMCS (Table  IV) . A significant regression equation was found with an R 2 of 0.326. The independent predictors of the ΔPCS were the baseline PCS and type of AF (PAF = 1), with an R 2 of KATO, ET AL (Table V) . Neither the BNP level nor LAD was a predictor of the ΔPCS (Table V) .
Discussion
In this study, the QOL improved in patients with AF after a single ablation procedure in association with maintenance of sinus rhythm. However, the effects of PVI on QOL differed between the PerAF and PAF groups. In the PAF group, both the MCS and PCS improved as assessed using the SF-36. Although most patients in the PerAF group were subjectively asymptomatic, the PCS improved without any changes in the MCS in the PerAF group, and the increase in the PCS was greater in the PerAF group than in the PAF group. Multiple linear regression analysis revealed that a greater increase in the MCS could be expected in patients with PAF and a low MCS score before PVI and that a greater increase in the PCS could be expected in those with PerAF and a low PCS score before PVI. QOL in patients with PerAF: Previous studies have demonstrated an improvement in QOL after successful PVI in patients with symptomatic AF. [1] [2] [3] [4] In the present study, many symptomatic patients were included in the PAF group, and our results regarding patients with PAF were compatible with those in previous studies. Bulková, et al. 11) described an improvement in the QOL after catheter ablation of PAF and long-standing PerAF. The QOL was assessed by the EuroQOL visual analog scale and EuroQOL 3-level and 5-dimensional descriptive system, QUALITY OF LIFE IN PERSISTENT ATRIAL FIBRILLATION but not by the SF-36 survey. The authors showed a greater improvement in the QOL in patients with long-standing PerAF than in patients with PAF. 11) Considering our results, their observation may be at least partly due to greater physical than mental benefits.
Yagishita, et al. 12) assessed QOL using the SF-36 survey in 34 patients with asymptomatic PerAF and reported an increase in the PCS and absence of significant changes in the MCS in 30 of the 34 patients with no AF recurrence after PVI. These findings are compatible with our study. In contrast, Mohanty, et al. 13) reported improvements in both the PCS and MCS following successful ablation in 61 patients with asymptomatic longstanding PerAF. The patients in the study by Yagishita, et al. 12) and those in our study were Japanese, and such inconsistent results regarding the effects of maintaining sinus rhythm in patients with PerAF may be partly explained by racial differences or differences in other baseline patient characteristics and/or the follow-up period among the studies.
The above-mentioned previous studies 12, 13) and our study showed an improvement in the PCS after retention of sinus rhythm following PVI in patients with subjectively asymptomatic PerAF. The current study expanded the previous studies by demonstrating that a lower PCS before ablation predicted its significant improvement following successful maintenance of sinus rhythm. The patients in the previous studies 12, 13) were asymptomatic, and most patients with PerAF in our study were also asymptomatic. The current expert consensus is that the effects of ablation on asymptomatic PerAF are uncertain, emphasizing the need for a careful discussion about the risks, benefits, and alternatives. Clinically, patients feel subjectively better after recovery of sinus rhythm from AF even if they claim no symptoms during the AF status. However, no predictor of the benefits of ablation has been established for patients with asymptomatic AF. Our study suggests that assessment of the PCS before ablation in patients with asymptomatic PerAF is useful for discriminating patients with PerAF who will gain benefits from the procedure. Future studies are necessary to confirm our hypothesis. Changes in plasma BNP level and QOL: The plasma BNP level is a well-known marker of the LV diastolic pressure and diastolic wall stress. 14, 15) The plasma BNP level decreases after restoration of sinus rhythm by cardioversion 16) or catheter ablation, 17) indicating the adverse effects on the LV loading condition through atrioventricular mechanical dyssynchrony during AF. 18) Yagishita, et al. 12) reported increases in the metabolic equivalents of the task and duration of maximal exercise and a decrease in the plasma BNP level in patients with asymptomatic PerAF following catheter ablation without recurrence of AF. They found a linear correlation between the increased duration of exercise and decreased plasma BNP level. In the present study, the plasma BNP level decreased in association with the restoration of sinus rhythm after the ablation; however, the change in the plasma BNP level was not an independent determinant of the improvement in the PCS. In the study by Yagishita, et al., 12) the relationship between the change in the plasma BNP level and the change in the PCS was not assessed. However, the differ-ent effects of the changes in the BNP level on exercise tolerance and the PCS may be explained by exercise tolerance and the PCS being partially independent of each other, possibly representing different constructs. Different QOL outcomes of ablation in patients with PerAF and PAF: In the current study, most patients with PerAF were subjectively asymptomatic; however, > 90% of patients with PAF were symptomatic. The PCS improved in both groups, but the improvement was more prominent in the patients with PerAF than in those with PAF. AF is intermittent in patients with PAF and does not necessarily restrict physical activity during sinus rhythm. This may at least partly explain the lesser increase in the PCS in the PAF group after ablation. In contrast, the MCS improved only in the PAF group. Most patients in the PAF group had symptoms related to PAF, and the disappearance of these symptoms after ablation might have dispelled their anxiety and stabilized their mental status. Most of the patients with PerAF reported no symptoms. Thus, they were unlikely to be aware of the freedom from AF after the ablation, and the MCS did not change. Although the MCS consists of VT, SF, RE, and MH of the SF-36 subscales, the values of PF, RP, BP, and GH (the components of PCS) were also incorporated in the formula used to calculate the MCS. In that formula, the coefficient of RP is a negative value, and an increase in RP results in a decrease in the MCS value. In the PerAF group, the increase in RP was large in comparison with the changes in the other seven components (Table II) . This likely explains why ΔMCS in the PerAF group was a negative value (Table III) , although the change in MCS after PVI was not statistically significant. In the PAF group, although the increase in RP was also large, its increase was smaller than that in the PerAF group. In addition, the increases in VT and MH in the PAF group were larger than those in the PerAF group (Table II) . Therefore, ΔMCS was a positive value in the PAF group, and the change in the MCS after PVI was significant. Limitations: We acknowledge several limitations of our study. First, the number of patients was small, and the study was a single-center study. Second, the patients who developed AF recurrence after the blanking period (4 patients with PAF and 2 with PerAF) were excluded. Although their data may have been valuable to clarify the benefits of maintenance of sinus rhythm, the number of patients with AF recurrence was too small to allow comparison of the QOL between patients with and without AF recurrence after PVI. Third, the follow-up data were obtained only 6 months after PVI; thus, the detailed time course of the changes in QOL after PVI is unclear. Fourth, patients with a low LVEF were excluded, which may explain why most of the patients with PerAF were asymptomatic. The LVEF improves after successful ablation, and the effects of maintaining sinus rhythm in patients with AF may differ between patients with a preserved and reduced LVEF. Thus, the results of this study may not be extrapolated to patients with AF who have a low LVEF.
